Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

The invention relates to a crystal (C) consisting of at least 95% by weight of 4,4′-dichlorodiphenylsulfoxide, 0 to 2% by weight of impurities and 0 to 3% by weight of an organic solvent (os). Moreover, the present invention relates to a crystal composition (CC) comprising crystals (C) and a process for the production of the crystal composition (CC) and the crystal (C).

The invention relates to a crystal (C) consisting of at least 95% by weight of 4,4′-dichlorodiphenylsulfoxide, 0 to 2% by weight of impurities and 0 to 3% by weight of an organic solvent (os). Moreover, the present invention relates to a crystal composition (CC) comprising crystals (C) and a process for the production of the crystal composition (CC) and the crystal (C).

The present invention concerns a process for the production of magnesium N-acetyl taurinate, in particular a process for the production of magnesium N-acetyltaurinate dihydrate.

The present invention concerns a process for the production of magnesium N-acetyl taurinate, in particular a process for the production of magnesium N-acetyltaurinate dihydrate.

The present invention relates to a process for the manufacturing of methane sulfonic acid (MSA) by reaction of a radical initiator composition with methane and sulfur trioxide comprising the steps (a) preparation of the intiator composition by reacting aqueous hydrogen peroxide with the components methane sulfonic acid and methane sulfonic acid anhydride and (b) reaction of the initiator composition from step (a) with sulfur trioxide and methane to form methane sulfonic acid. The invention further relates to the use of methane sulfonic acid anhydride (MSA anhydride) in said process and to methane sulfonic acid manufactured by said process.

The present invention relates to a process for the manufacturing of methane sulfonic acid (MSA) by reaction of a radical initiator composition with methane and sulfur trioxide comprising the steps (a) preparation of the intiator composition by reacting aqueous hydrogen peroxide with the components methane sulfonic acid and methane sulfonic acid anhydride and (b) reaction of the initiator composition from step (a) with sulfur trioxide and methane to form methane sulfonic acid. The invention further relates to the use of methane sulfonic acid anhydride (MSA anhydride) in said process and to methane sulfonic acid manufactured by said process.

The present invention deals with a process for the production of alkanesulfonic acids, in particular methanesulfonic acid, and a method of purification of the raw products.

The present invention deals with a process for the production of alkanesulfonic acids, in particular methanesulfonic acid, and a method of purification of the raw products.